Effects of dopaminergic drug adjustment on executive function in different clinical stages of Parkinson’s disease

Effects of dopaminergic drug adjustment on executive function in different clinical stages of Parkinson’s disease

Hidetomo Murakami, Tetsuhito Nohara, Hidenobu Shozawa, Yoshiyuki Owan, Takeshi Kuroda, Satoshi Yano, Machiko Kezuka, Mitsuru Kawamura, Kenjiro Ono Department of Neurology, School of Medicine, Showa University, Tokyo, Japan Background: Effects of dopaminergic medication on executive function in pat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Murakami H, Nohara T, Shozawa H, Owan Y, Kuroda T, Yano S, Kezuka M, Kawamura M, Ono K
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2017
Materias:
Parkinson disease
Executive function
Motor disorders
Dopaminergic drug
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Acceso en línea:https://doaj.org/article/4c416acae88b43c083837cf66669186a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:4c416acae88b43c083837cf66669186a
record_format dspace
spelling oai:doaj.org-article:4c416acae88b43c083837cf66669186a2021-12-02T06:13:04ZEffects of dopaminergic drug adjustment on executive function in different clinical stages of Parkinson’s disease1178-2021https://doaj.org/article/4c416acae88b43c083837cf66669186a2017-10-01T00:00:00Zhttps://www.dovepress.com/effects-of-dopaminergic-drug-adjustment-on-executive-function-in-diffe-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Hidetomo Murakami, Tetsuhito Nohara, Hidenobu Shozawa, Yoshiyuki Owan, Takeshi Kuroda, Satoshi Yano, Machiko Kezuka, Mitsuru Kawamura, Kenjiro Ono Department of Neurology, School of Medicine, Showa University, Tokyo, Japan Background: Effects of dopaminergic medication on executive function in patients with Parkinson’s disease (PD) are inconsistent. Objective: We examined the effect of dopaminergic medication on executive function in 24 drug-naïve PD patients (de novo group) and in 21 PD patients on chronic dopaminergic medication (chronic medication group). Methods: PD patients without dementia were included in this study. For the de novo group patients, dopaminergic medication was initiated, and the dose was increased to improve motor symptoms. For the chronic medication group patients, dopaminergic medication was adjusted to relieve clinical problems. All participants were tested prior to and at 4–7 months after the drug initiation/adjustment. Executive function was assessed by using the Behavioral Assessment of the Dysexecutive Syndrome (BADS). Motor function was assessed by using the Unified Parkinson’s Disease Rating Scale (UPDRS; part III). Improvement in executive function was compared with a simultaneous change in levodopa equivalent doses (LED) of dopaminergic medication and with improvement in motor functions. Results: The mean standardized BADS scores showed no significant improvement in both the groups. In the de novo group, percent improvement in the standardized BADS scores showed a significant positive correlation with the LED, but not with percent improvement in UPDRS part III. In the chronic medication group, percent improvement in the standardized BADS scores was negatively correlated with change in the LED, but not with percent improvement in UPDRS part III. Multiple regression analysis using improvement in the standardized BADS score as a dependent variable and patient’s background factors (ie, age, education, disease duration, and motor and executive assessments at baseline) as independent variable showed that improvement in the executive assessment is significantly correlated with the LED only in the de novo group. Conclusion: Effects of dopaminergic drug adjustment on executive function differ according to the patient’s clinical stage and depend on LED in de novo stage. Keywords: motor disorders, dopaminergic drug, levodopa equivalent dose, correlation between executive improvement and levodopa equivalent dose, inverted U-shaped theoryMurakami HNohara TShozawa HOwan YKuroda TYano SKezuka MKawamura MOno KDove Medical PressarticleParkinson diseaseExecutive functionMotor disordersDopaminergic drugNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 13, Pp 2719-2726 (2017)
institution DOAJ
collection DOAJ
language EN
topic Parkinson disease
Executive function
Motor disorders
Dopaminergic drug
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Parkinson disease
Executive function
Motor disorders
Dopaminergic drug
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Murakami H
Nohara T
Shozawa H
Owan Y
Kuroda T
Yano S
Kezuka M
Kawamura M
Ono K
Effects of dopaminergic drug adjustment on executive function in different clinical stages of Parkinson’s disease
description Hidetomo Murakami, Tetsuhito Nohara, Hidenobu Shozawa, Yoshiyuki Owan, Takeshi Kuroda, Satoshi Yano, Machiko Kezuka, Mitsuru Kawamura, Kenjiro Ono Department of Neurology, School of Medicine, Showa University, Tokyo, Japan Background: Effects of dopaminergic medication on executive function in patients with Parkinson’s disease (PD) are inconsistent. Objective: We examined the effect of dopaminergic medication on executive function in 24 drug-naïve PD patients (de novo group) and in 21 PD patients on chronic dopaminergic medication (chronic medication group). Methods: PD patients without dementia were included in this study. For the de novo group patients, dopaminergic medication was initiated, and the dose was increased to improve motor symptoms. For the chronic medication group patients, dopaminergic medication was adjusted to relieve clinical problems. All participants were tested prior to and at 4–7 months after the drug initiation/adjustment. Executive function was assessed by using the Behavioral Assessment of the Dysexecutive Syndrome (BADS). Motor function was assessed by using the Unified Parkinson’s Disease Rating Scale (UPDRS; part III). Improvement in executive function was compared with a simultaneous change in levodopa equivalent doses (LED) of dopaminergic medication and with improvement in motor functions. Results: The mean standardized BADS scores showed no significant improvement in both the groups. In the de novo group, percent improvement in the standardized BADS scores showed a significant positive correlation with the LED, but not with percent improvement in UPDRS part III. In the chronic medication group, percent improvement in the standardized BADS scores was negatively correlated with change in the LED, but not with percent improvement in UPDRS part III. Multiple regression analysis using improvement in the standardized BADS score as a dependent variable and patient’s background factors (ie, age, education, disease duration, and motor and executive assessments at baseline) as independent variable showed that improvement in the executive assessment is significantly correlated with the LED only in the de novo group. Conclusion: Effects of dopaminergic drug adjustment on executive function differ according to the patient’s clinical stage and depend on LED in de novo stage. Keywords: motor disorders, dopaminergic drug, levodopa equivalent dose, correlation between executive improvement and levodopa equivalent dose, inverted U-shaped theory
format article
author Murakami H
Nohara T
Shozawa H
Owan Y
Kuroda T
Yano S
Kezuka M
Kawamura M
Ono K
author_facet Murakami H
Nohara T
Shozawa H
Owan Y
Kuroda T
Yano S
Kezuka M
Kawamura M
Ono K
author_sort Murakami H
title Effects of dopaminergic drug adjustment on executive function in different clinical stages of Parkinson’s disease
title_short Effects of dopaminergic drug adjustment on executive function in different clinical stages of Parkinson’s disease
title_full Effects of dopaminergic drug adjustment on executive function in different clinical stages of Parkinson’s disease
title_fullStr Effects of dopaminergic drug adjustment on executive function in different clinical stages of Parkinson’s disease
title_full_unstemmed Effects of dopaminergic drug adjustment on executive function in different clinical stages of Parkinson’s disease
title_sort effects of dopaminergic drug adjustment on executive function in different clinical stages of parkinson’s disease
publisher Dove Medical Press
publishDate 2017
url https://doaj.org/article/4c416acae88b43c083837cf66669186a
work_keys_str_mv AT murakamih effectsofdopaminergicdrugadjustmentonexecutivefunctionindifferentclinicalstagesofparkinsonrsquosdisease
AT noharat effectsofdopaminergicdrugadjustmentonexecutivefunctionindifferentclinicalstagesofparkinsonrsquosdisease
AT shozawah effectsofdopaminergicdrugadjustmentonexecutivefunctionindifferentclinicalstagesofparkinsonrsquosdisease
AT owany effectsofdopaminergicdrugadjustmentonexecutivefunctionindifferentclinicalstagesofparkinsonrsquosdisease
AT kurodat effectsofdopaminergicdrugadjustmentonexecutivefunctionindifferentclinicalstagesofparkinsonrsquosdisease
AT yanos effectsofdopaminergicdrugadjustmentonexecutivefunctionindifferentclinicalstagesofparkinsonrsquosdisease
AT kezukam effectsofdopaminergicdrugadjustmentonexecutivefunctionindifferentclinicalstagesofparkinsonrsquosdisease
AT kawamuram effectsofdopaminergicdrugadjustmentonexecutivefunctionindifferentclinicalstagesofparkinsonrsquosdisease
AT onok effectsofdopaminergicdrugadjustmentonexecutivefunctionindifferentclinicalstagesofparkinsonrsquosdisease
_version_ 1718399988815364096

Ejemplares similares